Rev-erbα agonist GSK4112 treatment in primary human lung fibroblasts and IPF lung tissue explant cultures have been shown to reduce TGFβ1-induced activation of ECM genes Acta2 and Col1a1 [9]. Here, COL1A1 is linked to idiopathic pulmonary fibrosis.